Researchers dig into past data to uncover M7824's hidden side effects

NCT ID NCT04267861

Ongoing Knowledge-focused Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: M7824 (an immunotherapy drug)
What this could lead to: If successful, this could help doctors better manage or prevent side effects of M7824, leading to safer cancer treatments.
What could go wrong: This is a retrospective review of existing data, not a new treatment test. It may not capture all side effects or predict future risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS SKIN NEOPLASMS

Contacts and locations

Locations

National Cancer Institute (NCI)

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.